Policy Analysis and Program Evaluation

Gryphon’s science policy analysis reflects years of experience assessing the implications of enabling technologies and working to strengthen the biosafety and biosecurity of many nations. Our program evaluation portfolio focuses on learning how to strengthen the delivery and outcomes of health services and the impact of public health programs.

CASE STUDIES

01

Addressing the Potential Misuse of Synthetic DNA

A Gryphon analysis of policy options for regulating the synthetic biology industry included interviews with industry to understand their needs, limitations and existing security practices. We balanced this information with a technical threat assessment that examined how commercially produced synthetic DNA could be misused by a malicious actor. Our work resulted in HHS’ development of voluntary screening guidance that has been widely adopted by industry and remains a model of how to balance industry needs with security interests.
02

Meeting Unmet Needs for Veterinary Biologics

Gryphon investigated critical gaps in the development of veterinary biologics that might be addressed by a new government laboratory. By analyzing the literature, we identified key needs for novel biologics to prevent animal disease outbreaks. Through interviews with private sector stakeholders, we then determined which capabilities were lacking in industry and whether natural market forces might address those gaps.
03

Implementing U.S. Biosecurity and Biodefense Policy.

Gryphon collaborated on an ambitious, systems-based analysis of biosecurity and biodefense policy in the United States, highlighting direct and indirect effects of the policies on U.S. biodefense objectives. The results were presented in a roadmap for implementing biosecurity and biodefense policy that maximizes the benefits of science and technology advances while minimizing risks. See results here.